

## Case Report Form of PIROUETTE-PTA Study (Screening and Randomization)

Mark : Yes : "v"、No : "—"、Not done: "ND"、Not applicable : "NA"  
Fill up every item.

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

- A. Inclusion: > 20 y/o with LEAD documented by angiography\_\_\_\_(DSA\_\_\_\_ ; CTA\_\_\_\_; MRA\_\_\_\_) or sonography by operator\_\_\_\_\_
- B. Exclusion criteria: known CAD or unstable angina within past 3 months\_\_\_\_; acute myocardial infarction within past 6 months\_\_\_\_; known CAD status posterior PCI or bypass surgery within past 6 months\_\_\_\_; planning to do bypass surgery for known LEAD\_\_\_\_; pregnancy\_\_\_\_; documented active malignancy\_\_\_\_; needing emergency PTA\_\_\_\_; withdrawal of consent\_\_\_\_\_
- C. Grouping: routine\_\_\_\_(fill J-1); selective\_\_\_\_(fill J-2); registry\_\_\_\_\_
- D. Underlying: DM\_\_\_\_(type 1\_\_\_\_; type 2\_\_\_\_) for \_\_\_\_\_years ; insulin-used DM\_\_\_\_ ; HTN\_\_\_\_ ; HL\_\_\_\_ ; Smoking\_\_\_\_(quitted≥ 3yrs\_\_\_\_; quitted< \_\_\_\_\_3yrs\_\_\_\_; current\_\_\_\_) ; CAD\_\_\_\_ ; CAD S/P PCI\_\_\_\_ ; CAD S/P CABG\_\_\_\_ ; history of MI\_\_\_\_ ; history of CVA\_\_\_\_(ischemic\_\_\_\_ ; hemorrhagic\_\_\_\_ ; unidentified\_\_\_\_) ; S/P PTA\_\_\_\_; S/P bypass for LEAD\_\_\_\_ ; PUD\_\_\_\_ ; CKD\_\_\_\_(Stage\_\_\_\_) ; ESRD\_\_\_\_for\_\_\_\_years ; Non-ambulatory\_\_\_\_(totally bedridden\_\_\_\_ ; wheelchair bound\_\_\_\_) ;

Version: \_\_\_\_\_; Total pages:\_\_\_\_\_

CRF001(Version3.0; 2015.01.05) Confidential

anemia \_\_\_\_\_ ; CHF \_\_\_\_\_ (EF ≥ 40% \_\_\_\_\_ ; < 40% \_\_\_\_\_) ; others \_\_\_\_\_

E. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

F. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

G. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ; Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ; CCB \_\_\_\_\_ ( ) ; Statin \_\_\_\_\_ ( ) ; Fibrate \_\_\_\_\_ ( ) ; TZD \_\_\_\_\_ ( ) ; DPP4i \_\_\_\_\_ ( ) ; GLP-1 \_\_\_\_\_ ( ) ; others \_\_\_\_\_ (specify \_\_\_\_\_)

H. Lab (on admission for cath or PTA as baseline lab data)

	Albumin	AC sugar	BUN	Cr	Na	K	GPT	TC	TG	HDL	LDL	eGFR
unit	g/dL	mg/dL		mmol/L		U/L	mg/dL			mL/min/1.73m <sup>2</sup>		

Hb	WBC	PLT	N (Seg+Band)	L (lymphocytes)
g/dL	10 <sup>3</sup> /μl		%	

I

	BW (Kg)	BH (cm)	SBP (mmHg)	DBP (mmHg)	HR (/min)

J.

1. Actually receiving coronary angiography: Yes\_\_\_\_; No\_\_\_\_(why, specify\_\_\_\_)

2. Actually receiving stress test: Yes\_\_\_\_; No\_\_\_\_(why, specify\_\_\_\_)

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Cath)

Mark : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

Fill up every item.

Center ID: \_\_\_\_\_ Completion: in case \_\_\_\_\_ Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. Date of coronary angiography \_\_\_\_\_; Time elapsed from screening: \_\_\_\_\_  
days; Indications: routine \_\_\_\_\_; positive stress \_\_\_\_\_ (DSE \_\_\_\_\_; dTS \_\_\_\_\_;  
TXT \_\_\_\_\_); symptoms suggestive of angina \_\_\_\_\_ (stable \_\_\_\_\_; unstable \_\_\_\_\_;  
MI \_\_\_\_\_); EKG suggestive of CAD \_\_\_\_\_; cardiac enzymes suggestive of ACS \_\_\_\_\_;  
Holter suggestive of ischemia \_\_\_\_\_; cardiac echo suggestive of CAD \_\_\_\_\_; MSCTA  
suggestive of CAD \_\_\_\_\_

B. Results of coronary angiography: normal \_\_\_\_\_; non-obstructive atherosclerosis \_\_\_\_\_;  
CAD \_\_\_\_\_

C. If tick CAD in "B": LM \_\_\_\_\_; 4VD \_\_\_\_\_; 3VD \_\_\_\_\_; 2VD \_\_\_\_\_; 1VD \_\_\_\_\_; Syntax  
score \_\_\_\_\_

D. Vessels involved (if tick CAD in "B"): LM \_\_\_\_\_; LAD \_\_\_\_\_ ; LCX \_\_\_\_\_; RCA \_\_\_\_\_;  
IM \_\_\_\_\_; arterial graft \_\_\_\_\_ (LIMA \_\_\_\_\_ to which vessel \_\_\_\_\_; RIMA \_\_\_\_\_ to  
which vessel \_\_\_\_\_ ; others, specify \_\_\_\_\_ to which vessel \_\_\_\_\_); venous graft \_\_\_\_\_  
(SVG1 \_\_\_\_\_ to which vessel \_\_\_\_\_; SVG2 \_\_\_\_\_ to which vessel \_\_\_\_\_ ; SVG3 \_\_\_\_\_  
to which vessel \_\_\_\_\_ ; others, specify \_\_\_\_\_ to which vessel \_\_\_\_\_)

Version: \_\_\_\_\_; Total pages: \_\_\_\_\_

CRF002(2015.01.05; Version3.0) Confidential

E. Complications of coronary angiography: No\_\_\_\_; Yes\_\_\_\_(specify:\_\_\_\_\_)

F. Immediate outcomes of coronary angiography: No event\_\_\_\_; Events\_\_\_\_  
(non-fatal MI\_\_\_\_; non-fatal stroke\_\_\_\_; cardiovascular death\_\_\_\_ [fatal MI\_\_\_\_;  
fatal stroke\_\_\_\_] ; cardiogenic shock\_\_\_\_; sudden cardiac death\_\_\_\_] ; total  
death\_\_\_\_[specified \_\_\_\_\_])

G. Recommendation: Revascularization\_\_\_\_(PCI\_\_\_\_; CABG\_\_\_\_); Medical  
treatment \_\_\_\_\_

H. Final: Revascularization\_\_\_\_(PCI\_\_\_\_[fill form CRF003]; CABG\_\_\_\_[fill  
form CRF004]); Medical treatment \_\_\_\_\_)

I. Adjunct tools to facilitate confirmation of coronary severity: FFR\_\_\_\_ ; IVUS\_\_\_\_;  
OCT\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Version: \_\_\_\_\_; Total pages:\_\_\_\_\_

CRF002(2015.01.05; Version3.0) Confidential

## Case Report Form of PIROUETTE-PTA Study (PCI)

Mark : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

Fill up every item.

Center ID: \_\_\_\_\_ Completion: in case Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. Date of PCI \_\_\_\_\_; Time elapsed from screening: \_\_\_\_\_ days

B. How many vessels are intervened?: LM \_\_\_\_\_; 4 \_\_\_\_\_; 3 \_\_\_\_\_; 2 \_\_\_\_\_; 1 \_\_\_\_\_

C. Which vessels are intervened?:

1. LM \_\_\_\_\_ (POBA \_\_\_\_\_; BMS \_\_\_\_\_ [Multi-Link \_\_\_\_\_; Integrity \_\_\_\_\_; others, specify \_\_\_\_\_];  
DES \_\_\_\_\_ [Xience Prime \_\_\_\_\_; Resolute Integrity \_\_\_\_\_; others, specify \_\_\_\_\_])
2. LAD \_\_\_\_\_ (POBA \_\_\_\_\_; BMS \_\_\_\_\_ [Multi-Link \_\_\_\_\_; Integrity \_\_\_\_\_; others,  
specify \_\_\_\_\_]; DES \_\_\_\_\_ [Xience Prime \_\_\_\_\_; Resolute Integrity \_\_\_\_\_; others,  
specify \_\_\_\_\_])
3. LCX \_\_\_\_\_ (POBA \_\_\_\_\_; BMS \_\_\_\_\_ [Multi-Link \_\_\_\_\_; Integrity \_\_\_\_\_; others,  
specify \_\_\_\_\_]; DES \_\_\_\_\_ [Xience Prime \_\_\_\_\_; Resolute Integrity \_\_\_\_\_; others,  
specify \_\_\_\_\_])
4. RCA \_\_\_\_\_ (POBA \_\_\_\_\_; BMS \_\_\_\_\_ [Multi-Link \_\_\_\_\_; Integrity \_\_\_\_\_; others,  
specify \_\_\_\_\_]; DES \_\_\_\_\_ [Xience Prime \_\_\_\_\_; Resolute Integrity \_\_\_\_\_; others,  
specify \_\_\_\_\_])
5. IM \_\_\_\_\_ (POBA \_\_\_\_\_; BMS \_\_\_\_\_ [Multi-Link \_\_\_\_\_; Integrity \_\_\_\_\_; others, specify \_\_\_\_\_];  
DES \_\_\_\_\_ [Xience Prime \_\_\_\_\_; Resolute Integrity \_\_\_\_\_; others, specify \_\_\_\_\_])

Version: \_\_\_\_\_; Total pages: \_\_\_\_\_

CRF003(2015.01.05; Version3.0) Confidential

6. Artery graft \_\_\_\_ (LIMA \_\_\_\_; RIMA \_\_\_\_; others, specify \_\_\_\_) (POBA \_\_\_\_; BMS \_\_\_\_ [Multi-Link \_\_\_\_; Integrity \_\_\_\_; others, specify \_\_\_\_]; DES \_\_\_\_ [Xience Prime \_\_\_\_; Resolute Integrity \_\_\_\_; others, specify \_\_\_\_])
7. Venous graft \_\_\_\_ (SVG1 \_\_\_\_; SVG2 \_\_\_\_; SVG3 \_\_\_\_; others, specify \_\_\_\_) (POBA \_\_\_\_; BMS \_\_\_\_ [Multi-Link \_\_\_\_; Integrity \_\_\_\_; others, specify \_\_\_\_]; DES \_\_\_\_ [Xience Prime \_\_\_\_; Resolute Integrity \_\_\_\_; others, specify \_\_\_\_])

D. How many lesions are intervened?: \_\_\_\_\_

E. How many stents are deployed? \_\_\_\_\_

F. Complications of PCI: No \_\_\_\_; Yes \_\_\_\_ (specify: \_\_\_\_\_)

G. Immediate outcomes of coronary angiography: No event \_\_\_\_; Events \_\_\_\_ (non-fatal MI \_\_\_\_; non-fatal stroke \_\_\_\_; cardiovascular death \_\_\_\_ [fatal MI \_\_\_\_; fatal stroke \_\_\_\_; cardiogenic shock \_\_\_\_; sudden cardiac death \_\_\_\_] ; total death \_\_\_\_ [specified \_\_\_\_\_])

H. Results of PCI: Success \_\_\_\_ (complete \_\_\_\_; partial \_\_\_\_); failure \_\_\_\_\_

I. Cross over to CABG: No \_\_\_\_; Yes \_\_\_\_ (fill form CRF004)

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Version: \_\_\_\_\_; Total pages: \_\_\_\_\_

CRF003(2015.01.05; Version3.0) Confidential

## Case Report Form of PIROUETTE-PTA Study (CABG)

Center ID: \_\_\_\_\_ Completion: in case Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. Date of CABG \_\_\_\_\_; Time elapsed from screening: \_\_\_\_\_ days

B. Type: Elective \_\_\_\_\_; Urgency or Emergency \_\_\_\_\_

C. Beating heart \_\_\_\_\_; non-beating heart \_\_\_\_\_

D. How many vessels are bypassed?: 4 \_\_\_\_\_; 3 \_\_\_\_\_; 2 \_\_\_\_\_; 1 \_\_\_\_\_

E. Which vessels are bypassed?:

1. LAD \_\_\_(vein graft \_\_\_; artery graft \_\_\_)

2. LCX \_\_\_(vein graft \_\_\_; artery graft \_\_\_)

3. RCA \_\_\_(vein graft \_\_\_; artery graft \_\_\_)

4. IM \_\_\_(vein graft \_\_\_; artery graft \_\_\_)

F. How many grafts are implanted?: \_\_\_\_\_

G. Complications of CABG: No \_\_\_\_\_; Yes \_\_\_\_\_

H. Immediate outcomes of CABG: No event \_\_\_\_\_; Events \_\_\_\_\_(non-fatal MI \_\_\_\_\_;  
non-fatal stroke \_\_\_\_\_; cardiovascular death \_\_\_\_\_ [fatal MI \_\_\_\_\_; fatal stroke \_\_\_\_\_] ;

Current page: \_\_\_\_\_; Total pages: \_\_\_\_\_

CRF004 (2015.01.05; Version: 3.0) Confidential



cardiogenic shock\_\_\_\_; sudden cardiac death\_\_\_\_] ; total death\_\_\_\_  
[specified \_\_\_\_\_)]

I. Results of CABG: Success\_\_\_\_; failure \_\_\_\_\_

J. Cross over to PCI: No\_\_\_\_; Yes\_\_\_\_(fill form CRF003)

K. Duration of hospitalization:\_\_\_\_\_days

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (PTA)

Mark : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

Fill up every item.

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. Date of PTA \_\_\_\_\_; Time elapsed from screening: \_\_\_\_\_ days; Time elapsed from revascularization (PCI or CABG) \_\_\_\_\_ days; previous ipsilateral PTA \_\_\_\_\_; previous contralateral PTA \_\_\_\_\_; previous ipsilateral bypass \_\_\_\_\_; previous contralateral bypass \_\_\_\_\_

### B. Angiographic characteristics [TASC-II type sees J Vasc Surg 2007;45(supl S):S1-S67]

1. Rt lesions : Iliac \_\_\_\_\_ ( \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_ mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ; TASC-II type \_\_\_\_\_ ) ; Femopopliteal \_\_\_\_\_ ( \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_ mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ; TASC-II type \_\_\_\_\_ ) ; Infrapopliteal \_\_\_\_\_ ( \_\_\_\_\_ VD ; ATA \_\_\_\_\_ [ \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_ mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ] ; PTA \_\_\_\_\_ [ \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_ mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ] ; peroneal \_\_\_\_\_ [ \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_ mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ] ; number of tibial run-off \_\_\_\_\_ )

2. Lt lesions : Iliac \_\_\_\_\_ ( \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_

Version: \_\_\_\_\_; Total pages: \_\_\_\_\_

CRF005(2015.01.05; Version3.0) Confidential

mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ; TASC-II type \_\_\_\_\_) ;  
Femopopliteal \_\_\_\_\_ ( \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_  
mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ; TASC-II type \_\_\_\_\_) ;  
Infrapopliteal \_\_\_\_\_ ( \_\_\_\_\_ VD ; ATA \_\_\_\_\_ [ \_\_\_\_\_ % stenosis ;  
calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_ mm ; reference vessel size \_\_\_\_\_ mm ;  
collateral \_\_\_\_\_ ] ; PTA \_\_\_\_\_ [ \_\_\_\_\_ % stenosis ; calcification \_\_\_\_\_ ; lesion length  
mm ; reference vessel size \_\_\_\_\_ mm ; collateral \_\_\_\_\_ ] ; peroneal \_\_\_\_\_ [ \_\_\_\_\_ %  
stenosis ; calcification \_\_\_\_\_ ; lesion length \_\_\_\_\_ mm ; reference vessel size \_\_\_\_\_  
mm ; collateral \_\_\_\_\_ ] ; number of tibial run-off \_\_\_\_\_)

3. Right digital circulation : Grade \_\_\_\_\_

Left digital circulation : Grade \_\_\_\_\_

(P.S. : Grade 0 : no digital circulation ; Grade 1 : circulating flow to less than 5 toes or  
inadequate flow to 5 toes ; Grade 2: adequate flow to 5 toes)

4. Classification of pedal arch :

Right : type 1 \_\_\_\_\_ ; type 2A \_\_\_\_\_ ; type 2B \_\_\_\_\_ ; type 3 \_\_\_\_\_

Left : type 1 \_\_\_\_\_ ; type 2A \_\_\_\_\_ ; type 2B \_\_\_\_\_ ; type 3 \_\_\_\_\_

(P.S. : type 1 : both dorsalis pedis and plantar arteries patent ; type 2A : only dorsalis  
pedis patent ; type 2B : only plantar artery patent ; type 3 : both dorsalis pedis and  
plantar arteries occluded)

### **C. Angioplasty parameters**

1. Approach methods :

a. Antegrade \_\_\_\_\_ : transfemoral \_\_\_\_\_ (contralateral antegrade \_\_\_\_\_ ; ipsilateral  
antegrade \_\_\_\_\_) ; transbrachial antegrade \_\_\_\_\_

b. Retrograde \_\_\_\_\_ : distal SFA \_\_\_\_\_ ; popliteal \_\_\_\_\_ ; distal PTA \_\_\_\_\_ ;

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF005(2015.01.05; Version3.0) Confidential

dorsal pedis \_\_\_\_\_ ; others \_\_\_\_\_ [specify: \_\_\_\_\_])

2. Special devices used : laser \_\_\_\_\_; re-entry device \_\_\_\_\_ (off-road \_\_\_\_\_; outback \_\_\_\_\_; others \_\_\_\_\_ [specify \_\_\_\_\_]); rotablation \_\_\_\_\_ ; cutting balloon \_\_\_\_\_; distal embolism protection device \_\_\_\_\_ ; others \_\_\_\_\_ (specify: \_\_\_\_\_)

3. Methods for CTO lesions : subintimal tracking \_\_\_\_\_ ; Re-entry device \_\_\_\_\_ ; double-balloon technique \_\_\_\_\_; SAFARI technique \_\_\_\_\_ ; others \_\_\_\_\_ (specify: \_\_\_\_\_)

4. PTA for ilac \_\_\_\_\_ (Left \_\_\_\_\_ ; Right \_\_\_\_\_)

POBA \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

DEB \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

Stenting: Yes \_\_\_\_\_ (provisional \_\_\_\_\_; routine \_\_\_\_\_); No \_\_\_\_\_

BMS \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable stent \_\_\_\_\_ ; balloon-expandable stent \_\_\_\_\_; Brand : \_\_\_\_\_)

DES \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable stent \_\_\_\_\_ ; balloon-expandable stent \_\_\_\_\_; Brand : \_\_\_\_\_)

5. PTA for CFA or SFA \_\_\_\_\_ (Left \_\_\_\_\_ ; Right \_\_\_\_\_)

POBA \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

DEB \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

Stenting: Yes \_\_\_\_\_ (provisional \_\_\_\_\_; routine \_\_\_\_\_); No \_\_\_\_\_

BMS \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable stent \_\_\_\_\_ ; balloon-expandable stent \_\_\_\_\_; Brand : \_\_\_\_\_)

DES \_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable stent \_\_\_\_\_ ; balloon-expandable stent \_\_\_\_\_; Brand : \_\_\_\_\_)

6. PTA for popliteal \_\_\_\_\_ (Left \_\_\_\_\_ ; Right \_\_\_\_\_)

Version: \_\_\_\_\_; Total pages: \_\_\_\_\_

POBA\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

DEB\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

Stenting: Yes\_\_\_\_\_ (provisional\_\_\_\_\_ ; routine\_\_\_\_\_); No\_\_\_\_\_

BMS\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent\_\_\_\_\_ ; balloon-expandable stent\_\_\_\_\_ ; Brand : \_\_\_\_\_)

DES\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent\_\_\_\_\_ ; balloon-expandable stent\_\_\_\_\_ ; Brand : \_\_\_\_\_)

7. PTA for infrapopliteal\_\_\_\_\_ (Left\_\_\_\_\_ ; Right\_\_\_\_\_)

(1) PTA for ATA\_\_\_\_\_ (Left\_\_\_\_\_ ; Right\_\_\_\_\_)

POBA\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

DEB\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

Stenting: Yes\_\_\_\_\_ (provisional\_\_\_\_\_ ; routine\_\_\_\_\_); No\_\_\_\_\_

BMS\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent\_\_\_\_\_ ; balloon-expandable stent\_\_\_\_\_ ; Brand : \_\_\_\_\_)

DES\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent\_\_\_\_\_ ; balloon-expandable stent\_\_\_\_\_ ; Brand : \_\_\_\_\_)

(2) PTA for PTA\_\_\_\_\_ (Left\_\_\_\_\_ ; Right\_\_\_\_\_)

POBA\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

DEB\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

Stenting: Yes\_\_\_\_\_ (provisional\_\_\_\_\_ ; routine\_\_\_\_\_); No\_\_\_\_\_

BMS\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent\_\_\_\_\_ ; balloon-expandable stent\_\_\_\_\_ ; Brand : \_\_\_\_\_)

DES\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent\_\_\_\_\_ ; balloon-expandable stent\_\_\_\_\_ ; Brand : \_\_\_\_\_)

(3) PTA for peroneal artery\_\_\_\_\_ (Left\_\_\_\_\_ ; Right\_\_\_\_\_)

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

POBA\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

DEB\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Brand : \_\_\_\_\_) ;

Stenting: Yes \_\_\_\_\_ (provisional \_\_\_\_\_ ; routine \_\_\_\_\_) ; No \_\_\_\_\_

BMS\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent \_\_\_\_\_ ; balloon-expandable stent \_\_\_\_\_ ; Brand : \_\_\_\_\_)

DES\_\_\_\_\_ (size : \_\_\_\_\_ mm ; length : \_\_\_\_\_ mm ; Self-expandable  
stent \_\_\_\_\_ ; balloon-expandable stent \_\_\_\_\_ ; Brand : \_\_\_\_\_)

8. For SFA lesion, combined inflow intervention (iliac or CFA) \_\_\_\_\_ ; combined  
outflow intervention (infrapopliteal) \_\_\_\_\_

9. Complications : residual dissection \_\_\_\_\_ ; thrombus formation \_\_\_\_\_ ;  
dislodged stent \_\_\_\_\_ ; migrating stent with resultant uncovered  
lesion \_\_\_\_\_ ; vessel rupture \_\_\_\_\_ ; vascular access complications \_\_\_\_\_ ;  
shock \_\_\_\_\_ ; distal embolism \_\_\_\_\_ ; acute occlusion \_\_\_\_\_ ; others \_\_\_\_\_  
[specify: \_\_\_\_\_]

10. Immediate outcome : complete success \_\_\_\_\_ ; partial success \_\_\_\_\_ ;  
failure \_\_\_\_\_

11. If tick “complete success” or “partial success” in question 10:

Angiosome success \_\_\_\_\_ ; boundary success \_\_\_\_\_

12. After PTA,

Right digital circulation : Grade \_\_\_\_\_

Left digital circulation : Grade \_\_\_\_\_

(P.S. : Grade 0 : no digital circulation ; Grade 1 : circulating flow to less than 5 toes  
or inadequate flow to 5 toes ; Grade 2: adequate flow to 5 toes)

13. After PTA, pedal arch classification :

Right : type 1 \_\_\_\_\_ ; type 2A \_\_\_\_\_ ; type 2B \_\_\_\_\_ ; type 3 \_\_\_\_\_

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

Left : type 1 \_\_\_\_ ; type 2A \_\_\_\_ ; type 2B \_\_\_\_ ; type 3 \_\_\_\_

(P.S. : type 1 : both dorsalis pedis and plantar arteries patent ; type 2A : only dorsalis pedis patent ; type 2B : only plantar artery patent ; type 3 : both dorsalis pedis and plantar arteries occluded)

14. After PTA, wound brush (if there is an unhealed wound before PTA) will be

Right : No \_\_\_\_; Yes \_\_\_\_

Left : No \_\_\_\_; Yes \_\_\_\_

15. Immediate CV outcomes of PTA: No event \_\_\_\_; Events \_\_\_\_ (non-fatal MI \_\_\_\_; non-fatal stroke \_\_\_\_; cardiovascular death \_\_\_\_ [fatal MI \_\_\_\_; fatal stroke \_\_\_\_; cardiogenic shock \_\_\_\_; sudden cardiac death \_\_\_\_] ; total death \_\_\_\_ [specified \_\_\_\_\_])

16. Cross over to bypass surgery: No \_\_\_\_; Yes \_\_\_\_ (why, specific \_\_\_\_\_)

17. Procedure time: \_\_\_\_ min; Fluoro time: \_\_\_\_ min; Contrast used: \_\_\_\_ ml

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 1)

**Mark** : Yes : "v"、No : "—"、Not done: "ND"、Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_)

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Is it related to cath, PCI or CABG?
Symptom-free			NA	NA
Intermittent			NA	NA

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF006(2015.01.05; Version3.0) Confidential



claudication				
Resting pain or numbness			NA	NA
Ulcer wound			NA	NA
Gangrene			NA	NA
Minor amputation			NA	NA
Major amputation			NA	NA
Total Death			NA	No____; Yes_ (cath____; PCI____; CABG____) Cause of death: _____
CV death			NA	No____; Yes_ (cath____; PCI____; CABG____)
Cardiogenic shock			NA	No____; Yes_ (cath____; PCI____; CABG____)
Sudden cardiac death			NA	No____; Yes_ (cath____; PCI____; CABG____)
Fatal stroke			NA	No____; Yes_ (cath____; PCI____; CABG____)
Fatal MI			NA	No____; Yes_

				(cath____; PCI____; CABG____)
Non-fatal MI			NA	No____; Yes_ (cath____; PCI____; CABG____)
Non-fatal stroke			NA	No____; Yes_ (cath____; PCI____; CABG____)
CHF hospitalization			NA	No____; Yes_ (cath____; PCI____; CABG____)
New ESRD (in pts with no ESRD at baseline)			NA	No____; Yes_ (cath____; PCI____; CABG____)
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	NA
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____;	NA

			ABI____; CTA____; MRA____; DSA____)]; Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	NA
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	NA
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	NA
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]);	NA

			based on images ____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	NA

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 2)

**Mark** : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_ )

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Is it related to cath, PCI or CABG?
Symptom-free			NA	NA
Intermittent			NA	NA

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF007(2015.01.05; Version3.0) Confidential

claudication				
Resting pain or numbness			NA	NA
Ulcer wound			NA	NA
Gangrene			NA	NA
Minor amputation			NA	NA
Major amputation			NA	NA
Total Death			NA	No____; Yes_ (cath____; PCI____; CABG____) Cause of death: _____
CV death			NA	No____; Yes_ (cath____; PCI____; CABG____)
Cardiogenic shock			NA	No____; Yes_ (cath____; PCI____; CABG____)
Sudden cardiac death			NA	No____; Yes_ (cath____; PCI____; CABG____)
Fatal stroke			NA	No____; Yes_ (cath____; PCI____; CABG____)
Fatal MI			NA	No____; Yes_

				(cath____; PCI____; CABG____)
Non-fatal MI			NA	No____; Yes_ (cath____; PCI____; CABG____)
Non-fatal stroke			NA	No____; Yes_ (cath____; PCI____; CABG____)
CHF hospitalization			NA	No____; Yes_ (cath____; PCI____; CABG____)
New ESRD (in pts with no ESRD at baseline)			NA	No____; Yes_ (cath____; PCI____; CABG____)
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	NA
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____;	NA

			ABI____; CTA____; MRA____; DSA____)]; Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	NA
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	NA
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	NA
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]);	NA



			based on images ____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	NA

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 3)

**Mark** : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_ )

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Remarks
Symptom-free			NA	
Intermittent			NA	

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF008(2015.01.05; Version3.0) Confidential

claudication				
Resting pain or numbness			NA	
Ulcer wound			NA	
Gangrene			NA	
Minor amputation			NA	
Major amputation			NA	
Total Death			NA	
CV death			NA	
Cardiogenic shock			NA	
Sudden cardiac death			NA	
Fatal stroke			NA	
Fatal MI			NA	
Non-fatal MI			NA	
Non-fatal stroke			NA	
CHF hospitalization			NA	
New ESRD (in pts with no ESRD at baseline)			NA	
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]);	

			based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____	

			[duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 4)

**Mark** : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_ )

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Remarks
Symptom-free			NA	
Intermittent			NA	

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF009(2015.01.05; Version3.0) Confidential

claudication				
Resting pain or numbness			NA	
Ulcer wound			NA	
Gangrene			NA	
Minor amputation			NA	
Major amputation			NA	
Total Death			NA	
CV death			NA	
Cardiogenic shock			NA	
Sudden cardiac death			NA	
Fatal stroke			NA	
Fatal MI			NA	
Non-fatal MI			NA	
Non-fatal stroke			NA	
CHF hospitalization			NA	
New ESRD (in pts with no ESRD at baseline)			NA	
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]);	

			based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____	



			[duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 5)

**Mark** : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_ )

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Remarks
Symptom-free			NA	
Intermittent			NA	

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF010(2015.01.05; Version3.0) Confidential

claudication				
Resting pain or numbness			NA	
Ulcer wound			NA	
Gangrene			NA	
Minor amputation			NA	
Major amputation			NA	
Total Death			NA	
CV death			NA	
Cardiogenic shock			NA	
Sudden cardiac death			NA	
Fatal stroke			NA	
Fatal MI			NA	
Non-fatal MI			NA	
Non-fatal stroke			NA	
CHF hospitalization			NA	
New ESRD (in pts with no ESRD at baseline)			NA	
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]);	

			based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____	

			[duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 6)

**Mark** : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_ )

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Remarks
Symptom-free			NA	
Intermittent			NA	

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF011(2015.01.05; Version3.0) Confidential

claudication				
Resting pain or numbness			NA	
Ulcer wound			NA	
Gangrene			NA	
Minor amputation			NA	
Major amputation			NA	
Total Death			NA	
CV death			NA	
Cardiogenic shock			NA	
Sudden cardiac death			NA	
Fatal stroke			NA	
Fatal MI			NA	
Non-fatal MI			NA	
Non-fatal stroke			NA	
CHF hospitalization			NA	
New ESRD (in pts with no ESRD at baseline)			NA	
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]);	

			based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____	



			[duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 7)

**Mark** : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_ )

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Remarks
Symptom-free			NA	
Intermittent			NA	

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF012(2015.01.05; Version3.0) Confidential

claudication				
Resting pain or numbness			NA	
Ulcer wound			NA	
Gangrene			NA	
Minor amputation			NA	
Major amputation			NA	
Total Death			NA	
CV death			NA	
Cardiogenic shock			NA	
Sudden cardiac death			NA	
Fatal stroke			NA	
Fatal MI			NA	
Non-fatal MI			NA	
Non-fatal stroke			NA	
CHF hospitalization			NA	
New ESRD (in pts with no ESRD at baseline)			NA	
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]);	

			based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____	

			[duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Case Report Form of PIROUETTE-PTA Study (Visit 8)

**Mark** : Yes : "v" 、 No : "—" 、 Not done: "ND" 、 Not applicable : "NA"

**Fill up every item.**

Center ID: \_\_\_\_\_ Completion: Mandatory Date of form submission: \_\_\_\_\_

Patient ID: \_\_\_\_\_

Sex: \_\_\_\_\_ Age: \_\_\_\_\_ Time of Screening: \_\_\_\_\_

A. ABI : Lt \_\_\_\_\_ ; Rt \_\_\_\_\_ ; # Fontaine class \_\_\_\_\_ ; Rutherford class \_\_\_\_\_

B. Symptoms/signs : No \_\_\_\_\_ ; Yes \_\_\_\_\_ (intermittent claudication \_\_\_\_\_ ; leg swelling \_\_\_\_\_ ; cold foot \_\_\_\_\_ ; gangrene \_\_\_\_\_ ; poor healing wound (ulcer) \_\_\_\_\_ ; minor tissue loss \_\_\_\_\_ ; major tissue loss \_\_\_\_\_ ; others \_\_\_\_\_)

C. Drugs used: Bokey \_\_\_\_\_ ; Plavix \_\_\_\_\_ ; Ticagrelor \_\_\_\_\_ ; Ticocid \_\_\_\_\_ ;  
 Pletaal \_\_\_\_\_ ; Trental \_\_\_\_\_ ; Persantin \_\_\_\_\_ ; ACEI \_\_\_\_\_ ; ARB \_\_\_\_\_ ; DRI \_\_\_\_\_ ;  
 CCB \_\_\_\_\_ ( \_\_\_\_\_ ) ; Statin \_\_\_\_\_ ( \_\_\_\_\_ ) ; Fibrate \_\_\_\_\_ ( \_\_\_\_\_ ) ; TZD \_\_\_\_\_  
 ( \_\_\_\_\_ ) ; DPP4i \_\_\_\_\_ ( \_\_\_\_\_ ) ; GLP-1 \_\_\_\_\_ ( \_\_\_\_\_ ) ; others  
 (specified \_\_\_\_\_ )

D.

	Date of occurrence	Time elapse from Screening (days)	Is it planned staged PCI (or CABG) or PTA (or bypass)	Remarks
Symptom-free			NA	
Intermittent			NA	

Version: \_\_\_\_\_ ; Total pages: \_\_\_\_\_

CRF013(2015.01.05; Version3.0) Confidential

claudication				
Resting pain or numbness			NA	
Ulcer wound			NA	
Gangrene			NA	
Minor amputation			NA	
Major amputation			NA	
Total Death			NA	
CV death			NA	
Cardiogenic shock			NA	
Sudden cardiac death			NA	
Fatal stroke			NA	
Fatal MI			NA	
Non-fatal MI			NA	
Non-fatal stroke			NA	
CHF hospitalization			NA	
New ESRD (in pts with no ESRD at baseline)			NA	
TLR (PAD)			No____ (ischemia-driven____ [symptoms____]);	

			based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TVR (PAD)			No____ (ischemia-driven____ [symptoms____]; based on images____ [duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
TLR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
TVR (CAD)			No____ (ischemia-driven____ [symptoms____; stress test____]; based on images____ [CTA____; MRA____; cath____]); Yes____	
Any Revascularization for PAD			No____ (ischemia-driven____ [symptoms____]; based on images____	



			[duplex____; ABI____; CTA____; MRA____; DSA____]); Yes____	
Any revascularization for CAD			No____ (ischemia-driven____ [symptoms____; stress test____]); based on images____ [CTA____; MRA____; cath____]); Yes____	
Recurrent angina			NA	

Signature: \_\_\_\_\_ Date: \_\_\_\_\_